Loading...
Market
Top supplier of COVID-19 vaccine doses for 2024-2025 campaign by June 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Official reports from pharmaceutical companies and CDC procurement data
Story
CDC Recommends Second 2024-2025 COVID-19 Vaccine Dose for Seniors and Immunocompromised
Oct 24, 2024, 03:23 PM
The Centers for Disease Control and Prevention (CDC) has recommended a second dose of the 2024-2025 COVID-19 vaccine for individuals aged 65 and older, as well as those with moderately to severely weakened immune systems. This recommendation, made by the Advisory Committee on Immunization Practices (ACIP) on October 23, 2024, aims to enhance protection for these vulnerable groups. The CDC advises that the second dose should be administered six months after the initial dose, establishing a 6-month vaccine cadence. The policy is specific to the 2024-2025 period and includes provisions for immunocompromised individuals to receive additional doses in consultation with their clinicians.
View original story
Similar markets
Pfizer has the largest market share • 25%
Moderna has the largest market share • 25%
Novavax has the largest market share • 25%
Other companies have the largest market share • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Democratic Republic of Congo • 25%
Nigeria • 25%
South Africa • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
Africa CDC • 25%
Gavi • 25%
WHO • 25%
Other • 25%
Nigeria • 25%
Democratic Republic of the Congo • 25%
South Africa • 25%
Other • 25%
Novavax • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
Nigeria • 25%
Kenya • 25%
South Africa • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
GSK • 33%
Sanofi • 33%
Seqirus • 33%
Moderna • 25%
Pfizer • 25%
AstraZeneca • 25%
Other • 25%